Showing results (131-140 of 697) with videos related to
Sort By:
Pageof 70
American Journal of Hematology|July 28, 2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapiesNeil Majithia, S Vincent Rajkumar, Martha Q Lacy, et al.British Journal of Haematology|March 6, 2019
Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosisSurbhi Sidana, Nidhi Tandon, Morie A Gertz, et al.Blood Cancer Journal|January 16, 2024
Mode of progression in smoldering multiple myeloma: a study of 406 patientsNadine H Abdallah, Arjun Lakshman, Shaji K Kumar, et al.Archives of Dermatology|October 18, 2006
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myelomaHans P Sviggum, Mark D P Davis, S Vincent Rajkumar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2005
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology GroupS Vincent Rajkumar, Emily Blood, David Vesole, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendationsJoan Bladé, Meletios Dimopoulos, Laura Rosiñol, et al.Nature Reviews. Clinical Oncology|July 29, 2026
De-escalation trials in multiple myeloma: past, present and futureHira Mian, Luciano J Costa, Mohamad Mohty, et al.American Journal of Hematology|July 7, 2015
Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myelomaMoritz Binder, S Vincent Rajkumar, Morie A Gertz, et al.Blood Cancer Journal|April 15, 2020
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosisSurbhi Sidana, Paolo Milani, Moritz Binder, et al.American Journal of Hematology|June 19, 2023
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, et al.Pageof 70